Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
233
resultados
Última actualización
04/02/2026 [06:59:00]
Resultados 50 a 75 de 233
Resumen de: US20260028376A1
In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized sequences for antibody induction. In some embodiments, the invention provides mRNA sequences of said HIV-1 immunogens.
Resumen de: US20260028317A1
The present application is directed to a nanocage of Formula (I): wherein A and R are as described herein. The present application is also directed to an efficient process for preparation of a nanocage of Formula (I), which allows for efficient scale-up of the nanocage synthesis. Furthermore, this new process allows for rapid nanocage diversification, due a newly introduced late-stage functionalization method.
Resumen de: US20260028310A1
The invention relates to a compound, a lipid compound nanoparticle, a nucleic acid nanoparticle complex, a pharmaceutical composition and uses thereof in the drug delivery field, and belongs to the fields of biomedicine and biotechnology. The structure of the compound is shown as formula A. The compound, lipid compound nanoparticle or nucleic acid nanoparticle complex provided herein has the advantages of good biocompatibility, high transfection efficiency, low toxicity and excellent technical effects.
Resumen de: US20260027492A1
A porous hollow fiber membrane based anti-solvent crystallization (AsCr) process is disclosed. The process involves injecting an anti-solvent from a bore of a hollow fiber membrane into a shell side where a feed solution containing a solution containing a material, e.g., an API, is flowing. The shell-side feed solution flows perpendicular to the hollow fiber length; the shell side liquid is in cross flow across the hollow fiber membranes. Multiple HFM modules may be positioned in series with nanocrystal suspension product from one module fed to the next module that is independently fed with an anti-solvent. The crossflow HFM based continuous AsCr technique disclosed herein could result in continuous nanocrystal production of APIs.
Resumen de: US20260027200A1
Provided are a poxvirus mRNA vaccine and a use. Specifically, provided is an isolated mRNA molecule, comprising a coding region, the coding region coding a target protein, and the target protein comprising the following four proteins: vaccinia virus surface antigens A27, L1, A33, and B5, wherein every two adjacent proteins are independently directly linked or linked by identical or different linkers. Animal immunization results show that the mRNA molecule has good candidate vaccine potential and provides an innovative idea for the development of poxvirus vaccines.
Resumen de: CN120882692A
Compositions comprising lipid-like compounds, methods of making such compositions, and the use of these compositions in gene delivery applications are disclosed.
Resumen de: US20260027228A1
In one aspect, the disclosure relates to compounds methods for treating or preventing diseases associated with aberrant condensation of a biomolecule in a subject, the method including at least the step of contacting one or more cells in the subject with a fusion protein that includes a J domain protein and a targeting molecule, wherein the targeting molecule binds the biomolecule. In one aspect, the biomolecule can be a target protein that may be mutated and/or include one or more intrinsically disordered regions. In another aspect, the targeting molecule can be a nanobody, but other targeting molecules are also contemplated. In still another aspect, the disclosed method is useful for treating and/or preventing cancers such as blood cancers and non-small cell lung cancer. Also disclosed are methods for disrupting condensates in cell culture.
Resumen de: US20260027192A1
It pertains to a novel platform for the sustained release of Type-1 diabetes antigens. More specifically. it provides a combination of dual sized hydrogel particles for the delivery of Type-1 diabetes antigens and multi-component adjuvants to confer immune tolerance.
Resumen de: US20260027229A1
This disclosure provides an engineered delivery system, including a bacterial membrane vesicle derived from bacteria and one or more non-bacterial proteins for anchoring to the bacterial membrane vesicle.
Resumen de: US20260027211A1
The present invention relates to ultrasound (US) mediated delivery of therapeutic agents, such as the delivery of a drug, gene, nanoparticle or radioisotope, using a bi-phasic microparticle system comprising gas microbubbles, emulsion microdroplets and clusters thereof. Thus, the present invention relates to a cluster composition and a pharmaceutical composition, and their use for delivery of therapeutic agents and as a contrast agent for ultrasound imaging. It further relates to methods for delivering such therapeutic agents and to the use of said compositions.
Resumen de: US20260027140A1
Disclosed are compositions and methods for treating, amelioriating, reversing and/or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and/or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.
Resumen de: CN120857947A
Certain aspects of the invention relate to a method of preparing a concentrated nucleic acid composition comprising: (a) combining in an aqueous medium (i) a DNA plasmid comprising a nucleic acid encoding a human IL-12 polypeptide, (ii) a cationic lipid polymer comprising polyethylene glycol (PEG)-polyethyleneimine (PEI)-cholesterol (PPC), and (iii) a filler excipient, wherein the nucleic acid is complexed with the cationic lipid polymer, thereby forming a mixture of nucleic acids having a concentration of at least 0.15 mg/mL; and (b) concentrating the nucleic acid mixture of (a) by tangential flow filtration to form a concentrated nucleic acid composition having a concentration of at least 0.75 mg/mL, wherein the concentrated nucleic acid composition is suitable for pharmaceutical use, storage at-20 DEG C or less, 4 DEG C or less, and/or lyophilization. The invention further relates to pharmaceutical compositions prepared using the disclosed methods and methods of using the same.
Resumen de: CN120813369A
The present invention provides methods of increasing antigenicity or immunogenicity of a tumor in a subject. The method comprises the step of delivering lipid nanoparticles loaded with mRNA encoding one or more pathogen antigen proteins into the tumor.
Resumen de: WO2024163465A1
The disclosure provides mRNA vaccines for treating or preventing Epstein-Barr virus infection. The mRNA vaccines encode lytic and/or latent EBV antigens.
Resumen de: AU2024213807A1
Provided herein are RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include RNA molecules encoding viral replication proteins and antigenic proteins or fragments thereof, and lipids. RNA molecules and compositions including them are useful for inducing immune responses.
Resumen de: US2025332103A1
The present disclosure relates to a method for manufacturing a nanobubble-based drug delivery vehicle using a circle type focused ultrasonic technology, and a nanobubble-based drug delivery vehicle manufactured thereby, and more specifically, to a method for manufacturing a drug delivery vehicle using a circle type focused ultrasonic technology, the drug delivery vehicle including a shell, and a drug and nanobubbles contained inside the shell, and a nanobubble-based drug delivery vehicle manufactured thereby.
Resumen de: US2025268839A1
The invention relates to therapeutic nanobiologic compositions and methods of treating patients who have cancer, by promoting trained immunity, which is the long-term increased responsiveness, the result of metabolic and epigenetic re-wiring of myeloid cells and their stem cells and progenitors in the bone marrow and spleen and blood induced by a primary insult, and characterized by increased cytokine excretion after re-stimulation with one or multiple secondary stimuli.
Resumen de: WO2026024528A1
A process for removing Pb2+ ions from fluids is disclosed. More particularly, an intracorporeal process for removing Pb2+ ions from gastrointestinal fluids is disclosed. The process involves contacting gastrointestinal fluid with a titanate-based ion exchanger represented by the empirical formula: AmTiOz where A is sodium, potassium, lithium, magnesium, calcium, hydronium, or mixtures thereof. The alkali titanate ion exchanger is synthesized from specific Ti reagents, including nano-sized TiO2 and preformed spray dried TiO2 spheres, that impart properties such as favorable particle size and particle size distributions that are beneficial for treating the body.
Resumen de: AU2024212425A1
Disclosed herein are modified lipid compositions comprising (a) a structural component comprising one or more lipids selected from the group consisting of soy-derived lipids, cardiolipin, sphingolipid, ceramide, glucosyl ceramide, lactosyl ceramide, galactosyl cholesterol, glucosyl cholesterol; and modified by (b) an ionizable lipid. The disclosure also includes a method for making a modified lipid composition, comprising reconstructing (a) a structural component comprising one or more lipids selected from the group consisting of soy-derived lipids, cardiolipin, sphingolipid, ceramide, glucosyl ceramide, lactosyl ceramide, galactosyl cholesterol, and/or glucosyl cholesterol in the presence of (b) an ionizable lipid, to produce the modified lipid composition, and loading into the modified lipid composition with one or more heterologous functional agents.
Resumen de: CN120897737A
An aqueous dispersion having an aqueous mobile phase and a dispersed phase is described wherein: the dispersed phase comprises a lipid mixture comprising a cationically ionizable lipid; and the aqueous mobile phase comprises a buffer solution having a pH of from about 6.5 to about 8; wherein the aqueous dispersion is substantially free of inorganic cations, organic solvents, and nucleic acids. Methods of making the aqueous dispersions, nucleic acid-lipid particles, methods of making them using the aqueous dispersions, and their use in medicine are disclosed.
Resumen de: CN120897737A
An aqueous dispersion having an aqueous mobile phase and a dispersed phase is described wherein: the dispersed phase comprises a lipid mixture comprising a cationically ionizable lipid; and the aqueous mobile phase comprises a buffer solution having a pH of from about 6.5 to about 8; wherein the aqueous dispersion is substantially free of inorganic cations, organic solvents, and nucleic acids. Methods of making the aqueous dispersions, nucleic acid-lipid particles, methods of making them using the aqueous dispersions, and their use in medicine are disclosed.
Resumen de: CN120897737A
An aqueous dispersion having an aqueous mobile phase and a dispersed phase is described wherein: the dispersed phase comprises a lipid mixture comprising a cationically ionizable lipid; and the aqueous mobile phase comprises a buffer solution having a pH of from about 6.5 to about 8; wherein the aqueous dispersion is substantially free of inorganic cations, organic solvents, and nucleic acids. Methods of making the aqueous dispersions, nucleic acid-lipid particles, methods of making them using the aqueous dispersions, and their use in medicine are disclosed.
Resumen de: AU2023425729A1
A method of targeting antigen-presenting cells and delivering an encapsulated payload with lipid nanoparticles including a POZ-lipid conjugate. The encapsulated payload may include, but is not limited to, a nucleic acid payload such as mRNA or modified mRNA. These LNPs are not subject to accelerated blood clearance and they have a low or reduced immunogenicity profile in vivo.
Resumen de: WO2026024850A2
Described herein is a DNA nanostructure-based platform that can modulate a number of cellular functions depending on the concentration and surface decoration of the nanostructure. Utilizing different peptides for surface functionalization of DNA nanostructures, lysosomal activity was able to be modulated which in turn translated into the control of cellular functionality, ranging from changes in cell morphology to modulation of immune signaling and cell death. This demonstrates the rational design of a new generation of versatile DNA-based nanoplatforms that can be used in various biomedical applications such as the development of combinatorial anti-cancer platforms, efficient systems for endolysosomal escape, and nanoplatforms modulating lysosomal pH.
Nº publicación: WO2026024099A1 29/01/2026
Solicitante:
BIOARCHERS INC [KR]
\uC8FC\uC2DD\uD68C\uC0AC \uBC14\uC774\uC624\uC544\uCCD0\uC2A4
Resumen de: WO2026024099A1
The present invention relates to a drug carrier comprising mesoporous silica nanoparticles and, more specifically, to a carrier comprising mesoporous silica nanoparticles and a bioactive component, wherein the mesoporous silica nanoparticles have a predetermined diameter and surface zeta potential, and the bioactive component is a peptide containing a fatty acid chain. The carrier comprising mesoporous silica nanoparticles of the present invention effectively encapsulates peptides containing fatty-acid chains, and exhibits excellent intracellular delivery and release efficiency of the bioactive ingredient. Accordingly, effective drug delivery can be achieved with a small amount of the carrier.
BOPI
Sede Electrónica
